R Durie1,2, M Kohute2,3, C Fernandez4, M Knight4. 1. Cardiology, Jersey Shore University Medical Center, Neptune, NJ, USA. 2. Ernest Mario School of Pharmacy, Rutgers University, Neptune, NJ, USA. 3. Critical Care, Jersey Shore University Medical Center, Neptune, NJ, USA. 4. Jersey Shore University Medical Center, Neptune, NJ, USA.
Abstract
WHAT IS KNOWN AND OBJECTIVE: Given the data for four factor prothrombin complex concentrate (PCC) for vitamin K antagonist (VKA) reversal, there is great interest to determine whether PCC can improve patient outcomes in patients with bleeds associated with the newer oral anticoagulants (NOAC). CASE DESCRIPTION: We describe the case of an adult trauma patient anticoagulated with apixaban, presenting with a severe life-threatening bleed. PCC was administered at the maximum dose when the patient was determined to be refractory to supportive care with blood products. WHAT IS NEW AND CONCLUSION: Despite maximal treatment efforts, haemostasis was not achieved and the patient expired.
WHAT IS KNOWN AND OBJECTIVE: Given the data for four factor prothrombin complex concentrate (PCC) for vitamin K antagonist (VKA) reversal, there is great interest to determine whether PCC can improve patient outcomes in patients with bleeds associated with the newer oral anticoagulants (NOAC). CASE DESCRIPTION: We describe the case of an adult traumapatient anticoagulated with apixaban, presenting with a severe life-threatening bleed. PCC was administered at the maximum dose when the patient was determined to be refractory to supportive care with blood products. WHAT IS NEW AND CONCLUSION: Despite maximal treatment efforts, haemostasis was not achieved and the patient expired.
Authors: Amish N Raval; Joaquin E Cigarroa; Mina K Chung; Larry J Diaz-Sandoval; Deborah Diercks; Jonathan P Piccini; Hee Soo Jung; Jeffrey B Washam; Babu G Welch; Allyson R Zazulia; Sean P Collins Journal: Circulation Date: 2017-02-06 Impact factor: 29.690
Authors: Katrin Schmidt; Kerstin Krüger; Elisabeth Langer; Martin Schmutzler; Elke Johnen; Klaus D Wernecke; Christian von Heymann; Mareike K Körber Journal: Blood Transfus Date: 2018-05-08 Impact factor: 3.443